Coherus Biosciences - CHRS Net Assets per Single Share

Public company logo of coherus.com (CHRS)

Market dynamics confirm the strategy of Coherus Biosciences (CHRS), which combines biosimilar revenue with the development of new antineoplastic agents. A network of specialized warehouses ensures supply efficiency by providing clinics with medications. Simultaneously, the company is implementing a competitive corporate culture, motivating experts through stock options and KPIs. The current metric stands at 0.39, which correlates with the chosen course of business development.

CHRS - Coherus BioSciences Book Value of One Share over the range 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for Coherus BioSciences, Inc (CHRS)

- price and consensus price forecast:
Price Chart Coherus BioSciences Inc.|CHRS - Fair Value Consensus
- market capitalization data:
Market Value Coherus BioSciences, Inc.|CHRS - Company Buyout Price
- book capitalization data:
Book Value per Share Coherus BioSciences|CHRS - Book Value of Business|Market Capitalization to Book Value Ratio coherus.com|CHRS - Company Assets
- debt and liquidity data:
Debt to Equity Coherus Biosciences|CHRS - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Coherus Biosciences|CHRS - Company Cumulative Debt|Debt to Book Capitalization Ratio Coherus BioSciences, Inc.|CHRS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Coherus BioSciences
Fundamental company valuation:CHRS Coherus BioSciences
Manufactured product of Coherus BioSciences, Inc

The transformation of Coherus Biosciences (CHRS) toward immuno-oncology requires significant capital expenditures to strengthen the confidence of the medical community. The book value per share, calculated as the ratio of equity to the number of shares, demonstrates the actual value of net assets, separating the business's real foundation from market expectations, which allows for an assessment of intrinsic resilience through the current book value per share.

Competitors of Coherus Biosciences (CHRS)

Net Assets per Single Share Incyte Corp. (INCY)|HCM: Accounting Value of a Share|Nuvation Bio Inc. - Net Assets per Single Share|dayonebio.com (DAWN) - Net Assets per Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CRBP (Corbus Pharmaceuticals Holdings) - Book Value per Share|CRDF: Net Asset Value per Share|Net Assets per Single Share BeyondSpring Pharma BYSI|BioAtla (BCAB) - Accounting Value of a Share|LIXT (Lixte Biotechnology) - Book Value per Share|Book Value per Share CTXR|Net Assets per Single Share Cellectar Biosciences, Inc. (CLRB)|Net Assets per Single Share BioLineRx Ltd BLRX|Accounting Value per Share Can-Fite BioPharma, Ltd.|Aprea Therapeutics Inc. - Accounting Value of a Share|KZIA (Kazia) - Net Assets per Single Share|SLXN: Net Asset Value per Share|Net Assets per Single Share nucana.com|Chimerix Inc. (CMRX) - Equity per Share|Book Value per Share CYCC|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share